Ultragenyx cuts 20% of staff following failure of two rare disease drug programmes
Ultragenyx Pharmaceutical has announced it will lay off approximately 20% of its workforce after ending development of two rare disease drugs following trial failures.
Ultragenyx Pharmaceutical has announced that it is laying off approximately 20% of its staff after discontinuing development of two rare disease drug candidates. STAT News reported the news on 4 November 2026, noting that the cuts follow negative study results that forced the company to end both programmes.
Ultragenyx focuses specifically on rare and ultra-rare genetic metabolic diseases, making the dual failure particularly significant in terms of pipeline scope. The company did not release detailed data on the two failed assets in the item as reported, and no further mechanistic or clinical detail is available from the feed alone. Additional information is likely to follow in investor communications or scientific presentations.
The development is relevant to the rare disease genetics field for several reasons. First, it underlines the high attrition rate even for genetically validated targets in rare metabolic disease. Second, Ultragenyx has a track record of advancing therapies for conditions with very small patient populations, so programme discontinuation has a disproportionate impact on affected communities who may have few or no alternative treatments in development. Third, significant workforce reductions at a specialist rare-disease company can affect the capacity of a field that relies on small teams with deep expertise in specific disease areas.
The story sits alongside broader industry trends in which rising development costs and investor pressure are leading biotechnology companies to make faster portfolio prioritisation decisions, sometimes discontinuing programmes at an earlier stage than would historically have been the case.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-11-04STAT+: Ultragenyx cuts staff after another study fails